Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.
3 reports, 3 independent
Updated Aug 9
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Nektar Therapeutics receives FDA Fast Track designation while stock outperforms S&P 500.1 source
FDA granted Fast Track designation to rezpeg.1 source
Keep exploring
The entities involved
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
Related events
Coverage
Newest first; wire copies grouped- Motley FoolWhy Nektar Therapeutics Stock Popped 6% on Friday Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper
- ZacksNektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y Nektar Therapeutics NKTR reported a loss of $2.95 per share for the second quarter of 2025, narrower than the Zacks Consensus Estimate of a lo
- PR NewswireNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (